INTRODUCING OCCLUNOVA: AN IMPLANTABLE DEVICE FOR CHRONIC ATRIAL FIBRILLATION (AF)
PRESS RELEASE June 23, 2023 Founded by NLC, OccluNova is developing an implantable LAA closure device for people with chronic atrial fibrillation (AF) Atrial…
INTRODUCING THERAGENIX: GENE-BASED TISSUE REGENERATION
PRESS RELEASE June 12, 2023 TherageniX, an NLC venture, delivers genes for tissue repair and regeneration Disease, injuries and aging can damage body tissues….
INTRODUCING PROVASCTEC : A CELL THERAPY FOR PATIENTS WITH CRITICAL LIMB ISCHEMIA
PRESS RELEASE March 20, 2023 ProVascTec, an NLC venture, will help patients with critical limb ischemia by triggering cell induced new vascular tissue growth. …
INTRODUCING HEAT2MOVE: A NON-MEDICAL AND NON-INVASIVE PAIN RELIEVING TECHNOLOGY
PRESS RELEASE March 6, 2023 HEAT2MOVE, an NLC venture, sets out to provide a home care chronic pain relief option that is based on…
INTRODUCING ANSANA: A NEW STERILIZATION TECHNOLOGY FOR THE HEALTHCARE & PHARMACEUTICAL INDUSTRY.
PRESS RELEASE February 28, 2023 Ansana, an NLC venture, is on a mission to develop and launch a cutting-edge system for observing and confirming…
INTRODUCING CAREBED: A MOBILE-FRIENDLY SOLUTION FOR THE ELDERLY
PRESS RELEASE February 27, 2023 Carebed, an innovative bed that will increase a patient’s quality of life and reduce healthcare costs. Being dependent on…
SERDA therapeutics submits IND
PRESS RELEASE February 23, 2023 SERDA therapeutics submits IND for its lead product, an innovative wound debridement agent. SERDA therapeutics, a biopharmaceutical company, announces…
NC BIOMATRIX WINS EIC GRANT
PRESS RELEASE February, 15 2023 NC Biomatrix receives €2.5M European Innovation Council funding to complete pre-clinical studies and run its first-in-human trial Hundreds of…
MINDAFFECT AWARDED EUROSTARS GRANT
PRESS RELEASE February 15, 2023 MindAffect awarded Eurostar Grant for MAHDs – a groundbreaking EEG based Hearing Diagnostic System With approximately 175 million disabled…
NLC LAUNCHES FIRST IMPACT REPORT
PRESS RELEASE January 30, 2023 NLC is proud to announce their first Impact Report Regardless of their importance or creativity, 95% of all healthtech…